MedSci的“专业英语修改服务”更名为“专业审查润色”

2011-05-03 MedSci原创 MedSci原创

    随着MedSci发展,服务越来越深入,因此,对不少服务进行更为深度的划分,同时不断提高编辑的质量。从过去简单的语言修改服务(母语化润色服务),到对文章结构进行审查(专业审查润色),以及到现在对论文表述欠严谨,逻辑性欠妥,以及文章的创新性的提炼方面(专业改写服务),以及从课题设计开始进行审查(课题设计服务)。完全突破了同行公司仅能做简单的语言润色,帮助用户在临床

    随着MedSci发展,服务越来越深入,因此,对不少服务进行更为深度的划分,同时不断提高编辑的质量。从过去简单的语言修改服务(母语化润色服务),到对文章结构进行审查(专业审查润色),以及到现在对论文表述欠严谨,逻辑性欠妥,以及文章的创新性的提炼方面(专业改写服务),以及从课题设计开始进行审查(课题设计服务)。完全突破了同行公司仅能做简单的语言润色,帮助用户在临床科研方面,提供整合性服务平台。通过提供课题设计指导,帮助我们的客户从源头上,提升水平,防止大量临床研究成形后,出现难以弥补的漏洞,这是非常可惜的。对文章成文后,可以针对逻辑性,创新点方面进行提炼,有助于文章顺便发表SCI杂志,让中国作者的临床科研成果,能被国际同行认可和接受。

    为此,为了明确各项服务的特点,特将“专业英语修改服务”更名为“专业审查润色”,表明此项服务主要有两大步骤,首先是专业审查,在润色前,与作者一道,对文章的细节进行完善修改;然后再提交美国编辑进行语言润色。更名后,对服务的表述更为确切。对于已签订合同的客户,将执行原合同不变。原有的“专业英语修改服务”,也包含了专业审查和润色两个过程。

了解MedSci更多服务,请进入:https://www.medsci.cn/list.asp?classid=34

如果有任何疑问,请联系我们:https://www.medsci.cn/about.asp?id=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2235, encodeId=b97e223562, content=好,各取所需, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41144850, createdName=daihy520, createdTime=Fri May 06 17:08:00 CST 2011, time=2011-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497506, encodeId=816e149e5062a, content=<a href='/topic/show?id=21146026446' target=_blank style='color:#2F92EE;'>#更名#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60264, encryptionId=21146026446, topicName=更名)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5619335471, createdName=shalley69, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597823, encodeId=9554159e82319, content=<a href='/topic/show?id=993e658e5b2' target=_blank style='color:#2F92EE;'>#润色#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65875, encryptionId=993e658e5b2, topicName=润色)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750718527733, createdName=sunmin0225, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605588, encodeId=82c51605588b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=)]
    2011-05-06 daihy520

    好,各取所需

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2235, encodeId=b97e223562, content=好,各取所需, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41144850, createdName=daihy520, createdTime=Fri May 06 17:08:00 CST 2011, time=2011-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497506, encodeId=816e149e5062a, content=<a href='/topic/show?id=21146026446' target=_blank style='color:#2F92EE;'>#更名#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60264, encryptionId=21146026446, topicName=更名)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5619335471, createdName=shalley69, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597823, encodeId=9554159e82319, content=<a href='/topic/show?id=993e658e5b2' target=_blank style='color:#2F92EE;'>#润色#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65875, encryptionId=993e658e5b2, topicName=润色)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750718527733, createdName=sunmin0225, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605588, encodeId=82c51605588b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=)]
    2011-05-05 shalley69
  3. [GetPortalCommentsPageByObjectIdResponse(id=2235, encodeId=b97e223562, content=好,各取所需, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41144850, createdName=daihy520, createdTime=Fri May 06 17:08:00 CST 2011, time=2011-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497506, encodeId=816e149e5062a, content=<a href='/topic/show?id=21146026446' target=_blank style='color:#2F92EE;'>#更名#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60264, encryptionId=21146026446, topicName=更名)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5619335471, createdName=shalley69, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597823, encodeId=9554159e82319, content=<a href='/topic/show?id=993e658e5b2' target=_blank style='color:#2F92EE;'>#润色#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65875, encryptionId=993e658e5b2, topicName=润色)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750718527733, createdName=sunmin0225, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605588, encodeId=82c51605588b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=)]
    2011-05-05 sunmin0225
  4. [GetPortalCommentsPageByObjectIdResponse(id=2235, encodeId=b97e223562, content=好,各取所需, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41144850, createdName=daihy520, createdTime=Fri May 06 17:08:00 CST 2011, time=2011-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1497506, encodeId=816e149e5062a, content=<a href='/topic/show?id=21146026446' target=_blank style='color:#2F92EE;'>#更名#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60264, encryptionId=21146026446, topicName=更名)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5619335471, createdName=shalley69, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597823, encodeId=9554159e82319, content=<a href='/topic/show?id=993e658e5b2' target=_blank style='color:#2F92EE;'>#润色#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65875, encryptionId=993e658e5b2, topicName=润色)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=750718527733, createdName=sunmin0225, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605588, encodeId=82c51605588b4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 05 12:08:00 CST 2011, time=2011-05-05, status=1, ipAttribution=)]

相关资讯

肿瘤研究和临床SCI论文设计与发表讲座通知(2010.10.12上海)

肿瘤研究和临床SCI论文设计与发表通知

MedSci祝全年会员兔年大吉之贺卡

MedSci祝全年会员兔年大吉之贺卡

MedSci参加第四届国际生物医药产业发展创新论坛

    由中欧生物医药委员会(SEBMC)发起主办的第四届国际生物医药产业发展创新论坛暨国际创新药物研发与转化医学峰会于2011年4月21日正式开幕。来自美国、欧洲、中国及亚太地区的生物制药、新药研发、创新药物研发外包、医药临床研究、转化医学领域400多名代表和全球顶尖药物及医学专家参加本次会议。     MedSci代表也有幸参加了

MedSci 2011年五一放假通知

尊敬的MedSci客户和会员: 根据《国务院办公厅关于2011年部分节假日安排的通知》,为便于大家及早安排节假日事宜,MedSci 2011年五一劳动节放假安排如下: 4月30日至5月2日放假公休,共3天。5月3日(周二)正常上班 在放假期间,MedSci将不再安排相关客户服务支持等事宜,但仍然正常接收邮件,请发送邮件至 editing@medsci.cn,我们将在上班后尽快处理,敬请大

MedSci “临床科研中国行”全国巡回讲座(济南站 2010.11.20)

MedSci “临床科研中国行”全国巡回讲座——济南站